*3.11. Selective BTK Inhibitors*

Bruton's tyrosine kinase (BTK) is a member of the Tec family of tyrosine kinases involved in the high-affinity receptor for IgE (FcεRI)-dependent mast cell production of cytokines and degranulation [84,85], and in the IgE-mediated activation of human basophils [86]. BTK inhibitors could be useful to treat pathological mast cell responses of asthma [87].

A Phase II RCT [25] reported that orally administering remibrutinib (LOU064) 100 mg to inadequately controlled asthmatic patients did not induce an improvement in trough FEV1 and in morning and evening PEF compared to PCB. Changes in the ACQ5 score, in the asthma symptom score, and in the number of puffs of SABA taken daily were not different between remibrutinib and PCB groups [25].
